LSE:GSK
LSE:GSKPharmaceuticals

Is GSK’s 34% 2025 Rally Justified by Cash Flow and Earnings Prospects?

If you have been wondering whether GSK is still good value after its strong run, you are not alone. This piece will walk through what the current share price might really be implying. With the stock at around £18.26 and up 1.3% over the last week, 2.0% over the past month, and 34.1% year to date, the recent momentum suggests investors are reassessing both its growth prospects and risk profile. Recent headlines have focused on GSK sharpening its focus on vaccines and specialty medicines,...
NasdaqGS:TBBK
NasdaqGS:TBBKBanks

Bancorp (TBBK) Valuation Check After Recent Share Price Rebound

Bancorp (TBBK) has quietly marched higher, with the stock up around 8% over the past month and nearly 30% year to date, even as three month returns remain in the red. See our latest analysis for Bancorp. The recent bounce, including a 1 month share price return of about 8% and a 1 day gain that pushed the share price to $66.98, suggests momentum is cautiously rebuilding after a weak 3 month stretch, while longer term total shareholder returns remain robust. If Bancorp’s move has you thinking...
NasdaqGS:OTEX
NasdaqGS:OTEXSoftware

Is IDC’s AI Database Leadership Nod Reshaping The Investment Case For Open Text (OTEX)?

In 2025, OpenText was named a Leader in the IDC MarketScape for Worldwide Analytical Databases, reflecting the strength of its AI-powered OpenText Analytics Database, which supports real-time, petabyte-scale workloads across on-premises, private, and public cloud deployments with a focus on security and control. This recognition underscores OpenText’s growing relevance as enterprises modernize data analytics infrastructure and seek large-scale, secure AI analytics platforms to handle...
OM:ERIC B
OM:ERIC BCommunications

Does Ericsson’s 5G Rollout Justify Its Current Valuation After Recent Share Price Swings?

If you are wondering whether Telefonaktiebolaget LM Ericsson is quietly trading below what it is really worth, you are not alone, and that is exactly what we are going to unpack here. Despite a modest 2.0% gain over the last year, the stock has been choppy in the short term, slipping 1.0% over the past week and 4.8% over the last month, which can hint at shifting sentiment rather than a clear change in long term prospects. Recent headlines have centered on Ericsson's ongoing 5G network...
NasdaqGS:DCOM
NasdaqGS:DCOMBanks

Does the Market Misread Dime Community Bancshares After Its Recent Share Price Rebound?

If you have been wondering whether Dime Community Bancshares is quietly trading at a discount or already fully priced, you are not alone. This stock has been drawing interest from investors looking for value in regional banks. After a choppy stretch, the share price has bounced 4.0% over the last week and 12.5% across the past month, even though it is still down 1.9% year to date and 15.8% over the last year. This combination often signals shifting expectations rather than a simple momentum...
NYSEAM:GROY
NYSEAM:GROYMetals and Mining

Gold Royalty (NYSEAM:GROY): Valuation Check After Upsized Credit Facility and Balance Sheet Reset

Gold Royalty (NYSEAM:GROY) recently refreshed its balance sheet by upsizing and extending its revolving credit facility, improving borrowing costs and retiring high coupon debentures. This move directly affects how the company can fund future royalty acquisitions. See our latest analysis for Gold Royalty. Investors seem to be taking notice of this cleaner balance sheet, with Gold Royalty’s share price now at $4.16 and a strong year to date share price return of 235.48 percent reinforcing a...
ENXTPA:SAN
ENXTPA:SANPharmaceuticals

Sanofi (ENXTPA:SAN): Assessing Valuation After a Modest Short-Term Share Price Pullback

Short term performance and recent slide Sanofi (ENXTPA:SAN) has drifted lower recently, with the share price down around 1 % over the past week and about 2 % over the past month, even as the past 3 months remain positive. See our latest analysis for Sanofi. Despite the recent dip, Sanofi’s 6.38% 3 month share price return contrasts with a weaker year to date trend and a modest 1 year total shareholder return decline. This suggests sentiment is still recalibrating around growth prospects and...
NasdaqGS:DBX
NasdaqGS:DBXSoftware

Dropbox (DBX): Evaluating Valuation After a Period of Steady Shareholder Returns

Dropbox (DBX) has quietly outperformed many investors' expectations recently. The stock grinds higher on steady cash generation and disciplined costs, even while revenue growth has flattened and the broader software sector stays choppy. See our latest analysis for Dropbox. At around $29.94, Dropbox’s steady upward drift reflects investors warming to its reliable cash flows, with a 1 year total shareholder return of 4.21% building on a strong 3 year total shareholder return of 33.01%. If...
NYSE:BKE
NYSE:BKESpecialty Retail

Is It Too Late To Consider Buckle After A 200% Five Year Share Price Surge?

If you are wondering whether Buckle is still a smart buy after that long run up, or if you are showing up late to the party, this breakdown will give you a clear, valuation‑first view of where the stock stands today. With the share price at $57.41, Buckle has climbed 0.2% over the last week, 4.1% over the last month, 12.3% year to date and 15.7% over the past year, while longer term holders are sitting on gains of 64.2% over 3 years and 203.5% over 5 years. Recent market attention on the...
NYSE:TPL
NYSE:TPLOil and Gas

Texas Pacific Land (TPL): Assessing Valuation After Stock Split Move to Boost Liquidity and Accessibility

Texas Pacific Land (TPL) just set the stage for a stock split, filing to more than triple its authorized common shares ahead of a December 22 effective date. The move is squarely aimed at liquidity and accessibility. See our latest analysis for Texas Pacific Land. The stock split news lands just as Texas Pacific Land’s 1 day share price return of 5.79 percent and 7 day share price return of 6.0 percent signal building short term momentum, even though its 1 year total shareholder return of...
NYSE:FLUT
NYSE:FLUTHospitality

Why Flutter Entertainment (FLUT) Is Up 5.9% After Q3 Beat And FanDuel Predict Launch

Flutter Entertainment’s recent third‑quarter earnings report beat expectations, supported by strong U.S. iGaming growth, the rollout of FanDuel Predict, and contributions from recent acquisitions, reinforcing its position across key regulated markets. While the U.K.’s larger‑than‑anticipated online gaming tax increase adds cost pressure, the removal of regulatory uncertainty and continued cost‑saving initiatives have refocused attention on Flutter’s ability to grow and improve margins across...
ENXTPA:AI
ENXTPA:AIChemicals

L'Air Liquide (ENXTPA:AI): Assessing Valuation After a Three-Month Share Price Pullback

L'Air Liquide (ENXTPA:AI) has quietly pulled back over the past 3 months, even though earnings and revenue are still growing at a steady pace. That divergence is where the opportunity gets interesting. See our latest analysis for L'Air Liquide. Zooming out, that 90 day share price pullback of 6.94% comes after a solid year to date share price return of 4.71%. Longer term total shareholder returns above 50% suggest the underlying growth story is still intact, though short term momentum has...
NYSE:KVUE
NYSE:KVUEPersonal Products

Kenvue (KVUE) Valuation Check as Strategic Review Targets Portfolio Realignment and Higher-Margin Growth

Kenvue (KVUE) has kicked off a formal strategic review, and that is what has traders leaning in. A board-level committee is now evaluating divestitures, acquisitions, and capital shifts toward higher margin categories. See our latest analysis for Kenvue. The strategic review comes after a choppy stretch for the stock, with a 30 day share price return of 5.14 percent, but a year to date share price return of minus 20.25 percent and a 1 year total shareholder return of minus 23.69 percent,...
NasdaqCM:EXAS
NasdaqCM:EXASBiotechs

Has Exact Sciences Rally of Over 50% Left Room for Further Upside?

If you are wondering whether Exact Sciences is still a smart buy after its big run, or if you are late to the party, this breakdown will help you assess whether the current price reflects the company’s long term potential. The stock has cooled slightly over the last week, down 0.2%. However, that follows a 51.2% jump over the last month, gains of 77.9% year to date, and 57.9% over the past year. This naturally raises questions about how much upside may remain. Recent moves have been driven...
TSX:FVI
TSX:FVIMetals and Mining

Fortuna Mining (TSX:FVI): Valuation Check as Séguéla Expansion Study Targets Higher Gold Output

Fortuna Mining (TSX:FVI) just took a concrete step toward scaling up its Séguéla Mine in Côte d’Ivoire, awarding a study contract that could lift processing capacity and push annual gold output above 200,000 ounces. See our latest analysis for Fortuna Mining. That growth push has been mirrored in the market, with the share price up 15.61 percent over the past month and a strong 102.28 percent year to date share price return. The three year total shareholder return of 148.69 percent shows...
LSE:VOD
LSE:VODWireless Telecom

Does Vodafone’s 39.7% Rally Signal More Upside for the Telecom Giant in 2025?

How Has Vodafone Been Performing Lately? Vodafone Group has quietly staged a notable share price recovery, and those returns are exactly why investors are starting to ask whether the current price still represents value or if most of the upside has already been captured. Before looking at the numbers, it helps to understand how the stock has behaved over different time frames. Over the past year, Vodafone shares have delivered a gain of 39.7%, with most of that momentum building more...
NasdaqGM:TNDM
NasdaqGM:TNDMMedical Equipment

Taking Stock of Tandem Diabetes Care (TNDM) Valuation After Fresh Analyst Upgrades and Reaffirmed Optimism

Morgan Stanley's latest rating update on Tandem Diabetes Care (TNDM) has drawn additional attention on Wall Street, as several analysts increasingly align around a cautiously constructive view of the insulin pump maker. See our latest analysis for Tandem Diabetes Care. Those more upbeat views are landing just as sentiment around Tandem has started to thaw, with a roughly 39% 1 month share price return and a near 61% 3 month share price return. This contrasts with a still weak 1 year total...
NYSE:MPLX
NYSE:MPLXOil and Gas

Is MPLX Still Attractively Priced After Its Strong Multi Year Share Price Rally?

Wondering if MPLX is still a smart buy after such a big run, or if most of the value has already been squeezed out of the stock? Here is what the numbers are really saying about its current price. Over the last week MPLX is up 2.2%, about 7.8% over the past month, and it has climbed 12.7% year to date, 19.4% over the last year, 121.1% over three years, and 280.3% over five years. That kind of track record often makes investors ask whether they are late to the party or right on...
LSE:NG.
LSE:NG.Integrated Utilities

National Grid (LSE:NG.): Revisiting Valuation After a Strong Year of Defensive Outperformance

National Grid (LSE:NG.) has quietly outperformed over the past year, delivering a 23% total return while defensive utilities were out of favour. That raises a simple question for income investors: can this run continue? See our latest analysis for National Grid. That steady climb has not been a straight line, but the 19% year to date share price return, backed by an 80% five year total shareholder return, suggests momentum is still very much on National Grid’s side as investors reassess its...
NasdaqGS:RIVN
NasdaqGS:RIVNAuto

Is Rivian’s Surging Share Price Justified After Recent Production Ramp Up Hopes?

Wondering if Rivian Automotive's stock is finally at a buyable price, or if the recent excitement is getting ahead of the fundamentals? Let’s break down what the market is really pricing in. Rivian's share price has climbed 8.3% over the last week, 40.2% over the past month, and is now up 32.3% year to date. This follows a 42.1% rebound over the last year, after a tough 3 year stretch where it is still down 38.7%. Some of this renewed optimism has been driven by ongoing interest in EV...
LSE:AZN
LSE:AZNPharmaceuticals

Is AstraZeneca Still Attractive After Strong 2025 Rally and Pipeline Driven Revaluation?

Wondering if AstraZeneca is still a smart buy after its big run, or if you are late to the party? This breakdown will help you decide whether the current price really matches the long term story. The stock has slipped about 3.6% over the last week but is still up 7.9% over the past month, 27.1% year to date, and roughly 30.0% over the last year, suggesting strong momentum with a bit of recent cooling. Recently, AstraZeneca has stayed in the spotlight with a steady stream of pipeline updates...